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The main aim of this presentation is to give an overview
on the follow-up management of food anaphylactic
patients and to address the question of which patients
should be prescribed an epinephrine auto-injector (EAI)
in primary care. Practical recommendations on these
issues will be discussed.
A short introduction will be given on the definition
of anaphylaxis and the prevalence and incidence of
food anaphylaxis in primary care. Although definitions
of anaphylaxis do exist, it is not always easy to identify
anaphylaxis because the symptoms may be nonspecific
and variable. However, it has been shown that the inci-
dence and prevalence of anaphylaxis has increased in
primary care.
Once a patient has experienced an anaphylactic reac-
tion, follow-up management is very important. These
patients should be referred to an allergy specialist for
further evaluation of the food allergy. Meanwhile, these
patients should be prescribed an EAI and receive infor-
mation on how and when to use it. If the culprit food
allergen is know, the patient should receive information
about avoidance of this food.
In addition, the primary care physician may see other
food allergic patients as well who have not (yet) experi-
enced an anaphylactic reaction. In order to decide
which of these food allergic patients should be pre-
scribed an epinephrine auto-injector (EAI), an estima-
tion of the risk for anaphylaxis should be made. By
taking into account risk factors for anaphylaxis, patients
can be divided into low and high risk patients, which
will determine further management strategies.
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